Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Stem Cell Res. 2010 Aug 6;5(3):212–225. doi: 10.1016/j.scr.2010.07.003

Table 2A. Anti-CD19 antibodies do not inhibit engraftment of MCL tumor cells in NOD/SCID mice.

MCL patient cells were incubated with anti-CD19 antibodies, isotype controls and F(ab′)2 fragments of anti-CD19 antibodies before transplantation into NOD/SCID mice by intraperitoneal injection. F(ab′)2 fragments of anti-CD19 antibodies were generated by enzymatic digestion using ficin (Pierce) and then purified using a protein A column to remove Fc portions. MCL-like tumors formed at equal frequency in all mice.

Cells injected Cell dose # of mice tested Total # of mice have tumors
MCL tumor cells (pt1, pt3, pt8) + anti-CD19 antibodies 5×106 5 5/5 (100%)
MCL tumor cells (pt1, pt3, pt8) + IgG antibodies 5×106 3 3/3 (100%)
MCL tumor cells (pt1, pt3, pt8) + (Fab)2 fragments of CD19 5×106 4 4/4 (100%)